Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
58 participants
INTERVENTIONAL
2019-12-02
2023-03-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
4.1 Study population 1. AMD patients - intermediate and advanced AMD (with active or non-active CNV) 2. DR patients - with and without edema 4.2 Inclusion criteria
1. Ability and agreement to give informed consent (IC)
2. Diagnosis of AMD or DR in SE by OCT
3. Ability to undergo OCT scans
4. VA of 20/400 (6/120) or better in study eye(s)
4.3 Exclusion criteria
1\. Patient with dilated eye(s)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Home Retinal Imaging Using NOTAL-OCT V3.0
NCT04241198
Retinal Imaging Using NOTAL-OCT V2.5
NCT03600519
NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients
NCT03969303
Retinal Imaging Using NOTAL-OCT
NCT03374020
Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients
NCT05417152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For patients eligible to participate in the study, the following procedure will be done in the screening visit:
1. Patient will sign the IC (Informed Consent) form
2. Test the eligible eye(s) of the patient will be tested
3. The following demographic and clinical data will be collected for each tested eye and will be registered in the CRF:
1. Patient's DOB and gender.
2. Patient's diagnosis in study eye(s), based on patient's medical record, including media opacity (e.g. cataract or corneal opacity, if exists).
3. Examination to check habitual correction, pinhole VA and refraction.
4.5.2 OCT Visit 1: may take place on the same day as screening visit.
For each eligible eye, testing will include:
d. Refraction by auto-refractometer e. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube f. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. The patients will undergo an interactive tutorial that will teach the patient to self-operate the NOTAL-OCT V3.0 device. The tutorial will be done only once, using the eye with the better VA.
iii. To check repeatability, image capturing phase will include up to 8 testing sessions, each \~2 minutes long.
iv. Patients will rest for 5 minutes between sessions. v. Total examination time with NOTAL-OCT V3.0 is expected to be less than an hour.
vi. In case of patient's fatigue during the testing procedure, examination session will be terminated.
vii. The study staff will administer the NOTAL-OCT V3.0 "patient-experience" questionnaire at the 1st OCT Visit.
4.5.3 OCT Visits 2-6:
For each eligible eye, imaging will include:
a. Commercial OCT scanning: i. Scanning pattern: Macular cube of at least 6mm (20 degrees); At least 40 B-scans per cube b. NOTAL-OCT V3.0 scanning: i. Scanning pattern Macular cube of the central 10 degrees of the macula At least 40 B-scans per cube ii. Image capturing phase that will include up to 8 testing sessions, each a\~2 minutes long.
iii. Patients will rest for 5 minutes between sessions. iv. Total examination time with the NOTAL-OCT V3.0 is expected to be less than an hour.
v. In case of patient's fatigue during the testing procedure, examination will be terminated.
c. VA of eye(s) participating in the study. d. Clinical diagnosis of eye(s) participating in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMD
NOTAL-OCT V3.0 scan
NOTAL-OCT V3.0
AMD and DR patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NOTAL-OCT V3.0
AMD and DR patients
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Notal Vision Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assuta Hashalom
Tel Aviv, , Israel
Tel Aviv Medical Center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOTAL-OCT V3.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.